Radiopharmaceutical · Kills target cells, directed at gastrin-releasing peptide receptor (GRPR) · developed by ELI LILLY &
LY4257496 is a radioconjugate made of a gastrin-releasing peptide receptor (GRPR)-targeting ligand carrying a cytotoxic radioisotope. It binds GRPR-expressing tumor cells to deliver a cytotoxic radiation dose to them. It is being studied in breast, colorectal, prostate, endometrial, gastric and esophageal neoplasms.
Summary written with AI from the sources listed at the end of this page.
Breast NeoplasmsColorectal NeoplasmsEndometrial NeoplasmsEsophageal NeoplasmsNeoplasm MetastasisProstate NeoplasmStomach Neoplasms
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →